Nov 4, 2026
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q3 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.08 loss, and revenues of $53.23 million, exceeding estimates by 0.62%. The company's shares have gained approximately 18% year-to-date, outperforming the S&P 500. Currently, Cytek Biosciences holds a Zacks Rank #3 (Hold) as analysts anticipate further changes in estimates for the upcoming quarters.
Company relevance
99.75%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
Nov 4, 2026
Cytek Beats On A Gross Margin Surge, But Slowing Growth And A Fading EBITDA Outlook Leave A Rallied Stock Little Room For Error
Cytek Biosciences (CTKB) reported a Q3 beat driven by improved gross margins due to manufacturing efficiencies, with GAAP gross margin reaching 59%. However, revenue growth decelerated significantly to 1.8%, and the adjusted EBITDA outlook for the full year has eroded to "around break-even." While the company showed strength in its U.S. academic franchise and high-end instruments, the stock's recent rally leaves little room for error given the trimmed guidance and reliance on a strong Q4.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish